TNNT2 and familial dilated cardiomyopathy: In the present study, we found that candesartan improved the survival rate and cardiac systolic function, and suppressed progression of cardiac dilation and fibrosis using a DCM mouse model with the ΔK210 mutation in TNNT2, which closely recapitulates the human phenotype [12]–[14], [16].